Paper Details

  1. Home
  2. Paper Details

Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.

Author: AggarwalRahul Raj, BartelinkImke H, ChienAmy J, DhawanMallika S, GewitzAndrew, GrabowskyJennifer A, KelleyRobin K, LengJim, MaktabiTayeba, MoasserMark, MunsterPamela N, PawlowskaNela, Terranova-BarberioManuela, ThomasScott, ZhangJenna Z

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

The PARP inhibitor talazoparib showed efficacy when combined with carboplatin in patients with germline BRCA1/2 mutations. However, this combination therapy also had significant hematologic toxicity. Pharmacokinetic modeling suggests that intermittent dosing of talazoparib, differentiated by germline and somatic DNA damage mutation status, may improve the benefit-risk ratio of this treatment.
Paper Details　
Original Abstract of the Article :
<b>Purpose:</b> The PARP inhibitor (PARPi) talazoparib may potentiate activity of chemotherapy and toxicity in cells vulnerable to DNA damage.<b>Experimental Design:</b> This phase I study evaluated the safety, tolerability, pharmacokinetics, and efficacy of talazoparib and carboplatin. Pharmacokin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/1078-0432.CCR-17-0703

データ提供：米国国立医学図書館（NLM）

Tailoring Cancer Treatment: PARP Inhibition and DNA Repair Mutations

The field of [cancer treatment] is increasingly focused on [personalized medicine], tailoring therapies to individual patients. This Phase I study investigates the [safety, tolerability, and efficacy] of combining [the PARP inhibitor talazoparib] with [the chemotherapy drug carboplatin] in [patients with advanced solid tumors]. The researchers observed that this combination demonstrated [efficacy in patients with DNA repair mutations], particularly those with [germline BRCA1/2 mutations]. However, they also found that this combination was associated with [increased hematologic toxicity], especially in [patients with BRCA mutations]. This research highlights the [importance of considering individual genetic factors] when selecting cancer treatments.

Precision Medicine: A Step Towards Personalized Cancer Treatment

This study exemplifies the shift towards [precision medicine] in cancer treatment. By understanding the [role of DNA repair mutations] in response to therapy, we can [better predict and manage] the effects of treatment, tailoring it to individual patient needs.

Navigating the Desert of Cancer Treatment: Finding the Right Path

This research reminds us that [understanding the unique genetic makeup] of each patient is crucial in [developing effective and safe cancer therapies]. It's like navigating a desert landscape where different paths lead to different destinations. By [identifying the relevant genetic markers], we can [choose the most appropriate treatment path] for each individual, maximizing benefits while minimizing risks.

Dr. Camel's Conclusion

This study emphasizes the importance of considering individual genetic factors in cancer treatment. It's like navigating a desert where the landscape changes constantly: we need to stay vigilant and adapt our strategies to the unique challenges of each journey.

Date :
  1. Date Completed 2018-07-23
  2. Date Revised 2018-07-23
Further Info :

Pubmed ID

28790114

DOI: Digital Object Identifier

10.1158/1078-0432.CCR-17-0703

Related Literature

Article Analysis
・Side Effects of talazoparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.